Why it matters: Xaira is the landing spot for CEO Marc Tessier-Lavigne, the former Genentech chief scientific officer and Denali Therapeutics co-founder who last year resigned as Stanford ...

A prominent genetics professor at Stanford University in the US ... claimed he misled them whist persuading them to invest $20 million in the biotech, set up to develop a candidate therapy for ...

Stanford University genetics professor Dr. Stanley Cohen paid $29.2 million to settle a lawsuit over misleading claims he made about Nuredis Inc., his now-dissolved biotechnology company.

Strong financial positions reduce risk in biotech investing, prioritizing firms with both current and pipeline drugs. Vertex shows diversified drug development in chronic diseases, underscoring ...

"Instead of being beholden to the binary nature of biotech events, investing in a broader pool of biotech firms helps hedge risk for negative events while still having significant exposure to long ...

The Stanford Biotechnology Business & Finance Group ... in exploring careers in biotechnology business, management, and investment. This member driven group will host invited speakers from local ...

Stanford Chemist is a scientific researcher ... of generating profitable investments with CEFs and ETFs. He leads the investing group CEF/ETF Income Laboratory. Features of the service include ...

Find out why Europe has fallen behind the U.S. and China in the AI race in biotech and what it needs to do to catch up.